Bryostatin 1
- Generic Name
- Bryostatin 1
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C47H68O17
- CAS Number
- 83314-01-6
- Unique Ingredient Identifier
- 37O2X55Y9E
- Background
Bryostatin 1 has been investigated for the treatment of HIV Infection and Alzheimer's Disease.
- Associated Conditions
- -
- Associated Therapies
- -
Bryostatin and Vincristine in B-Cell Malignancies
- Conditions
- Recurrent Adult Lymphoblastic LymphomaRecurrent Grade 3 Follicular LymphomaRefractory Chronic Lymphocytic LeukemiaRefractory Multiple MyelomaStage III Multiple MyelomaRecurrent Adult Immunoblastic Large Cell LymphomaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Adult Diffuse Mixed Cell LymphomaRecurrent Adult Burkitt LymphomaRecurrent Mantle Cell Lymphoma
- Interventions
- First Posted Date
- 2004-03-19
- Last Posted Date
- 2013-01-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 18
- Registration Number
- NCT00003166
- Locations
- πΊπΈ
Case Western Reserve University, Cleveland, Ohio, United States
Bryostatin-1 Plus Cisplatin in Treating Patients With Recurrent or Advanced Cancer of the Cervix
- Conditions
- First Posted Date
- 2004-03-05
- Last Posted Date
- 2013-07-10
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Registration Number
- NCT00005965
- Locations
- πΊπΈ
Saint Vincent Catholic Medical Center of New York, New York, New York, United States
πΊπΈNYU School of Medicine's Kaplan Comprehensive Cancer Center, New York, New York, United States
πΊπΈNew York Presbyterian Hospital - Cornell Campus, New York, New York, United States
Cisplatin Plus Bryostatin 1 in Treating Patients With Advanced Cancer
- Conditions
- First Posted Date
- 2004-02-09
- Last Posted Date
- 2013-07-18
- Lead Sponsor
- Lombardi Comprehensive Cancer Center
- Registration Number
- NCT00003108
- Locations
- πΊπΈ
Lombardi Cancer Center, Washington, District of Columbia, United States
Combination Chemotherapy in Treating Patients With Unresectable Locally Advanced or Metastatic Stomach Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-07-25
- Last Posted Date
- 2012-07-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 37
- Registration Number
- NCT00006081
- Locations
- πΊπΈ
CCOP - M.D. Anderson Research Base, Houston, Texas, United States
πΊπΈUniversity of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Bryostatin 1 in Treating Patients With Ovarian Epithelial Cancer
- Conditions
- First Posted Date
- 2003-05-08
- Last Posted Date
- 2013-06-26
- Lead Sponsor
- University of Glasgow
- Registration Number
- NCT00004008
- Locations
- π¬π§
Royal Infirmary, Glasgow, Scotland, United Kingdom
π¬π§Christie Hospital N.H.S. Trust, Manchester, England, United Kingdom
π¬π§Weston Park Hospital, Sheffield, England, United Kingdom
Bryostatin 1 in Treating Patients With Stage IV Breast Cancer
- Conditions
- First Posted Date
- 2003-04-23
- Last Posted Date
- 2013-05-30
- Lead Sponsor
- University of Colorado, Denver
- Registration Number
- NCT00003205
- Locations
- πΊπΈ
University of Colorado Cancer Center, Denver, Colorado, United States
Bryostatin 1 Plus Vincristine in Treating Patients With Progressive or Relapsed Non-Hodgkin's Lymphoma After Bone Marrow or Stem Cell Transplantation
- Conditions
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueNodal Marginal Zone B-cell LymphomaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Adult Diffuse Mixed Cell LymphomaRecurrent Adult Diffuse Small Cleaved Cell LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone Lymphoma
- Interventions
- First Posted Date
- 2003-04-09
- Last Posted Date
- 2013-01-10
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 28
- Registration Number
- NCT00058305
- Locations
- πΊπΈ
Case Western Reserve University, Cleveland, Ohio, United States
Paclitaxel and Bryostatin 1 in Treating Patients With Metastatic Prostate Cancer
- First Posted Date
- 2003-03-07
- Last Posted Date
- 2019-11-04
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 46
- Registration Number
- NCT00005028
- Locations
- πΊπΈ
Wellspan Health - York Cancer Center, York, Pennsylvania, United States
πΊπΈGreater Baltimore Medical Center and Cancer Center, Baltimore, Maryland, United States
πΊπΈComprehensive Cancer Center at Wake Forest University, Winston-Salem, North Carolina, United States
Bryostatin 1 and Cytarabine in Treating Patients With Relapsed Acute Myelogenous Leukemia
- Conditions
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2010-03-01
- Lead Sponsor
- Virginia Commonwealth University
- Registration Number
- NCT00017342
- Locations
- πΊπΈ
Herbert Irving Comprehensive Cancer Center at Columbia University, New York, New York, United States
πΊπΈUniversity of Texas - MD Anderson Cancer Center, Houston, Texas, United States
πΊπΈNew York Weill Cornell Cancer Center at Cornell University, New York, New York, United States
Bryostatin 1 Plus Paclitaxel in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer or Stomach Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-21
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00005599
- Locations
- πΊπΈ
Albert Einstein Clinical Cancer Center, Bronx, New York, United States
πΊπΈMemorial Sloan-Kettering Cancer Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.